Evidence map›Paper›PMID 38744861›Full record

ArticleScientific reports2024

FT-Raman and FTIR spectroscopy as a tools showing marker of platinum-resistant phenomena in women suffering from ovarian cancer.

Marta Kluz-Barłowska, Tomasz Kluz, Wiesław Paja, Krzysztof Pancerz, Monika Łączyńska-Madera, Paulina Miziak, Jozef Cebulski, Joanna Depciuch

Abstract read
In one paragraph

Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Marta Kluz-BarłowskaDepartment of Pathology, Fryderyk Chopin University Hospital, F. Szopena 2, 35-055, Rzeszow, Poland. marta.kluz@interia.pl.
Tomasz KluzDepartment of Gynecology, Gynecology Oncology and Obstetrics, Fryderyk Chopin University Hospital, F. Szopena 2, 35-055, Rzeszow, Poland.
Wiesław PajaInstitute of Computer Science, College of Natural Sciences, University of Rzeszow, Rzeszow, Poland.
Krzysztof PancerzInstitute of Philosophy, John Paul II Catholic University of Lublin, Lublin, Poland.
Monika Łączyńska-MaderaDepartment of Gynecology, Gynecology Oncology and Obstetrics, Fryderyk Chopin University Hospital, F. Szopena 2, 35-055, Rzeszow, Poland.
Paulina MiziakDepartment of Biochemistry and Molecular Biology, Medical University of Lublin, 20-093, Lublin, Poland.
Jozef Cebulski *Institute of Physics, College of Natural Sciences, University of Rzeszow, 35959, Rzeszow, Poland.
Joanna Depciuch *Department of Biochemistry and Molecular Biology, Medical University of Lublin, 20-093, Lublin, Poland. joanna.depciuch@ifj.edu.pl.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Platinum-resistant phenomena in ovarian cancer is very dangerous for women suffering from this disease, because reduces the chances of complete recovery. Unfortunately, until now there are no methods to verify whether a woman with ovarian cancer is platinum-resistant. Importantly, histopathology images also were not shown differences in the ovarian cancer between platinum-resistant and platinum-sensitive tissues. Therefore, in this study, Fourier Transform InfraRed (FTIR) and FT-Raman spectroscopy techniques were used to find chemical differences between platinum-resistant and platinum-sensitive ovarian cancer tissues. Furthermore, Principal Component Analysis (PCA) and machine learning methods were performed to show if it possible to differentiate these two kind of tissues as well as to propose spectroscopy marker of platinum-resistant. Indeed, obtained results showed, that in platinum-resistant ovarian cancer tissues higher amount of phospholipids, proteins and lipids were visible, however when the ratio between intensities of peaks at 1637 cm

Indexed as

Drug Resistance, NeoplasmOvarian NeoplasmsPrincipal Component AnalysisSpectrum Analysis, RamanAgedBiomarkers, TumorFemaleHumansMachine LearningMiddle AgedPlatinumSpectroscopy, Fourier Transform InfraredBiomarkers, TumorPlatinumCorrelationFTIRFT-RamanMultivariate analysesPlatinum-resistant ovarian cancerROC

Identifiers

PMID38744861
PMCPMC11094164

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.